An antibody-drug conjugate targeting soluble and membrane-bound TGFα is effective against pancreatic tumors
These findings highlight TGFα as a promising therapeutic target in pancreatic cancer, supporting further preclinical and clinical development of TGFα-directed ADCs.
Authors
- Gabriel Capellá (ORCID: https://orcid.org/0000-0002-4669-7320)
- Atanasio Pandiella (ORCID: https://orcid.org/0000-0002-4704-8971)
- María Gómez–García (ORCID: https://orcid.org/0009-0003-3302-1895)
- Inés Romero-Pérez
- Juan Carlos Montero (ORCID: https://orcid.org/0000-0003-4773-053X)
- Mireia Morell-Ginestà
- Mónica Redondo-Puente
Institutions
- Instituto de Investigación Biomédica de Salamanca (ES)
- Centro de Investigación del Cáncer (ES)
- Centro de Investigación Biomédica en Red de Cáncer (ES)
Publication Details
- Journal
- Journal of Experimental & Clinical Cancer Research
- Published
- 2025-05-23
- DOI
- https://doi.org/10.1186/s13046-025-03421-8
- Citations
- 1
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- Ministerio de Economía y Competitividad
- Centro de Investigación Biomédica en Red de Cáncer
- Junta de Castilla y León
- CRIS Cancer Foundation
- Instituto de Salud Carlos III